Evidence map›Paper›PMID 27624329›Full record

ArticleBreast cancer research and treatment2016

Haplotype analyses of the c.1027C>T and c.2167_2168delAT recurrent truncating mutations in the breast cancer-predisposing gene PALB2.

Irene Catucci, Silvia Casadei, Yuan Chun Ding, Sara Volorio, Filomena Ficarazzi, Anna Falanga, Marina Marchetti, Carlo Tondini, Michela Franchi, Aaron Adamson and 10 more

Open access · greenAbstract read
In one paragraph

Article in Breast cancer research and treatment, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Analysis of ItalianCancers · 2021
    Article
  5. Article
  6. Article
  7. Genetic Cancer Risk Assessment for Breast Cancer in Latin America.Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 2 countries.

Irene CatucciIFOM, the FIRC Institute of Molecular Oncology, Milan, Italy.
Silvia CasadeiDepartments of Medicine and Genome Sciences, University of Washington School of Medicine, Seattle, WA, USA.
Yuan Chun DingDepartment of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA.
Sara VolorioCogentech, Cancer Genetic Test Laboratory, Milan, Italy.
Filomena FicarazziCogentech, Cancer Genetic Test Laboratory, Milan, Italy.
Anna FalangaDepartment of Immunohematology and Transfusion Medicine, Ospedale Papa Giovanni XXIII, Bergamo, Italy.
Marina MarchettiDepartment of Immunohematology and Transfusion Medicine, Ospedale Papa Giovanni XXIII, Bergamo, Italy.
Carlo TondiniUnit of Oncology, Ospedale Papa Giovanni XXIII, Bergamo, Italy.
Michela FranchiUnit of Oncology, Ospedale Papa Giovanni XXIII, Bergamo, Italy.
Aaron AdamsonDepartment of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA.
Jessica MandellDepartments of Medicine and Genome Sciences, University of Washington School of Medicine, Seattle, WA, USA.
Tom WalshDepartments of Medicine and Genome Sciences, University of Washington School of Medicine, Seattle, WA, USA.
Olufunmilayo I OlopadeDepartment of Medicine, Center for Clinical Cancer Genetics and Global Health, University of Chicago, Chicago, IL, USA.
Siranoush ManoukianUnit of Medical Genetics, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Paolo RadiceUnit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Charite RickerDepartment Medicine, Keck School of Medicine at University of Southern California, Los Angeles, CA, USA.
Jeffrey WeitzelDepartment of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA.
Mary-Claire KingDepartments of Medicine and Genome Sciences, University of Washington School of Medicine, Seattle, WA, USA.
Paolo PeterlongoIFOM, the FIRC Institute of Molecular Oncology, Milan, Italy.
Susan L NeuhausenDepartment of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA. sneuhausen@coh.org.ORCID 0000-0001-5053-0390
City of Hope · USOspedale Papa Giovanni XXIII · ITUniversity of Washington · USFondazione IRCCS Istituto Nazionale dei Tumori · ITIFOM · ITUniversity of Chicago · USUniversity of Southern California · US

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI STANLEY R. HAMILTON · 1985 to 2026
$86.3M
GENOMIC ANALYSIS OF INHERITED BREAST AND OVARIAN CANCERR35CA197458 · NCI · UNIVERSITY OF WASHINGTON · PI KING, MARY-CLAIRE · 2015 to 2021
$6.4M
Germline and Tumor Genomic Analyses of Breast Cancer in LatinasR01CA184585 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI NEUHAUSEN, SUSAN L., ZIV, ELAD · 2014 to 2018
$4.2M
COMPLETE VARIANT PROFILING OF ALL KNOWN BREAST CANCER GENESR01CA175716 · NCI · UNIVERSITY OF WASHINGTON · PI KING, MARY-CLAIRE, WALSH, TOMAS D · 2013 to 2017
$3.1M
NCI NIH HHS P30 CA033572NCI NIH HHS R01 CA175716NCI NIH HHS R01 CA184585NCI NIH HHS R35 CA197458
6 · The paper itself

Abstract

purposeBreast cancer-predisposing mutations PALB2 c.1027C>T (p.Gln343*) and PALB2 c.2167_2168delAT have each been observed multiple times in breast cancer families of Italian ancestry. More recently, the c2167_2168delAT mutation was identified in unrelated breast cancer cases of various ancestries. For each mutation, we investigated whether the origin was multiple mutational events (a "hot-spot") or a single event (a founder allele).

methodsWe genotyped and reconstructed haplotypes for 36 participants of Italian, Italian-American, Hispanic, and Nigerian ancestries, using seven short tandem repeat (STR) markers that covered 3 Megabases within and flanking PALB2 on chromosome 16.

resultsFor PALB2 c.1027C>T, a shared haplotype with a minimum size of 150 kb was shared by all 19 carriers investigated, all of Italian ancestry. This result suggests that this allele arose as a single event in a shared ancestor. For PALB2 c.2167_2168delAT, all 12 carriers from American-Italian and Italian families shared a 1-Mb haplotype, the 3 Hispanic carriers shared a different haplotype of size 2 Mb, and the Nigerian carrier had different alleles at all 7 STR markers. These results suggest that PALB2 c.2167_2168delAT arose multiple times, but that within each population, PALB2 c.2167_2168delAT likely represents a single mutational event.

conclusionWe identified two PALB2 mutations that are founder alleles in Italian families, one of which is, independently, also a founder mutation in American-Hispanic breast cancers.

Indexed as

AllelesGenetic Predisposition to DiseaseHaplotypesMutationBreast NeoplasmsFanconi Anemia Complementation Group N ProteinFemaleFounder EffectGenetic Association StudiesHeterozygoteHumansItalyMicrosatellite RepeatsPedigreeFanconi Anemia Complementation Group N ProteinBreast cancerFounder mutations, HaplotypePALB2

Identifiers

PMID27624329
PMCPMC5551669
OpenAlexW2519922470

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.